Hinge Health (NYSE:HNGE) Issues Quarterly Earnings Results, Beats Estimates By $0.27 EPS

Hinge Health (NYSE:HNGE) released its earnings results on Tuesday. The company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.27, Zacks reports.

Here are the key takeaways from Hinge Health’s conference call:

• Outstanding 2025 financials and bullish 2026 guide: Q4 revenue was $171M and full-year revenue was $588M (+51% YoY) with strong margins (85% gross margin in Q4) and a 2026 revenue guide of $732–742M with ~21% operating margin.
• AI-driven efficiency materially improved economics in 2025 — Hinge served 47% more members while keeping care team costs flat, reduced asynchronous care time by 28% QoQ, and rolled out “Robin” (92% positive member rating), enabling planned flat care-team sizing in 2026.
• Strong commercial momentum: the company added 4.8M net new contracted lives to ~24.6M, reported 97% client retention, expanded distribution with >60 ecosystem partners and greater penetration into fully insured/MA/FEP markets, and published a peer‑reviewed study showing 60% fewer imaging visits in its chronic back program.
• Hinge Select (in‑person provider network) shows promising early outcomes — ~85% of members moved to conservative care and some surgeries were avoided — but management does not expect meaningful revenue contribution from Hinge Select before 2027.
• Strong cash generation and capital allocation: $180M free cash flow in 2025 (31% margin), ~$479M cash on hand, and an active share repurchase program (1.4M shares bought for $65M in Q4; $250M authorized) to support shareholder value.

Hinge Health Stock Up 3.3%

Shares of HNGE traded up $1.06 during mid-day trading on Tuesday, hitting $33.22. 2,920,561 shares of the company’s stock traded hands, compared to its average volume of 1,050,159. The firm has a market capitalization of $2.62 billion and a P/E ratio of -2.53. The business’s 50-day moving average price is $44.38 and its 200-day moving average price is $49.02. Hinge Health has a 1 year low of $30.08 and a 1 year high of $62.18.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on HNGE. Canaccord Genuity Group upped their target price on Hinge Health from $61.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Piper Sandler reduced their target price on shares of Hinge Health from $71.00 to $60.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Stifel Nicolaus set a $59.00 price objective on Hinge Health in a research note on Thursday, February 5th. Weiss Ratings reissued a “sell (d)” rating on shares of Hinge Health in a research note on Thursday, January 22nd. Finally, KeyCorp reduced their price target on Hinge Health from $72.00 to $70.00 and set an “overweight” rating on the stock in a research report on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $59.63.

Insiders Place Their Bets

In related news, CEO Daniel Antonio Perez sold 166,665 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $46.38, for a total value of $7,729,922.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President James Pursley sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $48.40, for a total transaction of $726,000.00. Following the completion of the sale, the president owned 769,778 shares of the company’s stock, valued at $37,257,255.20. This trade represents a 1.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,805,105 shares of company stock valued at $128,216,614 over the last quarter.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. US Bancorp DE boosted its position in shares of Hinge Health by 96.1% during the third quarter. US Bancorp DE now owns 3,110 shares of the company’s stock valued at $153,000 after purchasing an additional 1,524 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Hinge Health during the third quarter valued at $157,000. Verition Fund Management LLC bought a new stake in shares of Hinge Health during the 3rd quarter valued at $238,000. Man Group plc purchased a new stake in shares of Hinge Health in the 2nd quarter worth about $267,000. Finally, Dark Forest Capital Management LP bought a new position in shares of Hinge Health in the 3rd quarter worth about $290,000.

Hinge Health announced that its Board of Directors has authorized a share buyback program on Wednesday, November 12th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 7.2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.